Personen > Professoren/-innen > Illges, Harald

Illges, Harald

Harald Illges

Prof. Dr. Harald Illges
Professor für Immunologie und Zellbiologie

von-Liebig-Str. 20
53359 Rheinbach
Bauteil A, Raum A 218

Telefon: +49 2241 865 570
FAX: +49 2241 865 8570

mailto:

Lehrveranstaltungen

  • Immunology (BSc Applied Biology)
  • Cell Biology (BSc Applied Biology)
  • Advanced and Clinical Immunology (MSc Biomedical Sciences)

Forschungsgebiete

  • Autoimmunität
  • Immundefekte
  • Komplement System
  • Neuroimmunologie

 Kooperationsfelder

 Sonderaufgaben (Selbstverwaltung)

  • Beauftragter für Studiengangsorganisation Biology ("Studiendekan Biologie")

 Veröffentlichungen (seit 2000)

  • Illges H., Braun M., Peter H.H. and I. Melchers. 2000. Reduced expression of the complement receptor type 2 (CR2, CD21) by synovial fluid B and T lymphocytes. Clin Exp Immunol 122:270-276.
  • Denz A., Eibel H., Illges H., Kienzle G., Schlesier M. and H.H. Peter. 2000. Impaired up-regulation of CD86 in B cells of "type A" common variable immunodeficiency patients.Eur J Immunol 30:1069-1077.
  • Allam A. and H. Illges. 2000. Calyculin A inhibits expression of CD8alpha but not CD4 in human peripheral blood T cells. Immunobiology 202:353-362.
  • Schwab J. and H. Illges. 2001. Regulation of CD21 expression by DNA methylation and histone deacetylation. Int Immunol 13:705-710.
  • Schwab J. and H. Illges. 2001. Silencing of CD21 expression in synovial lymphocytes is independent of methylation of the CD21 promoter CpG island. Rheumatol Int 20:133-137.
  • Solomon S., Masilamani M., Rajendran L., Bastmeyer M., Stuermer C.A. and H. Illges. 2002. The lipid raft microdomain-associated protein reggie-1/flotillin-2 is expressed in human B cells and localized at the plasma membrane and centrosome in PBMCs. Immunobiology 205:108-119. 
  • Solomon S., Kolb C., Mohanty S., Jeisy-Walder E., Preyer, R. Schollhorn V. and H. Illges. 2002. Transmission of antibody-induced arthritis is independent of complement component 4 (C4) and the complement receptors 1 and 2 (CD21/35). Eur J Immunol 32:644-651.
  • Shen H., Illges H., Reuter A. and C.A. Stuermer. 2002. Cloning, expression, and alternative splicing of neogenin1 in zebrafish. Mech Dev 118:219-223.
  • Mierau R. and H. Illges. 2002. Autoantibodies and the complement system--significance for pathogenesis of rheumatoid arthritis?. Z Rheumatol 61:460-463.
  • Masilamani M., von Seydlitz E., Bastmeyer M. and H. Illges. 2002. T cell activation induced by cross-linking CD3 and CD28 leads to silencing of Epstein-Barr virus/C3d receptor (CR2/CD21) gene and protein expression. Immunobiology 206:528-536.
  • Masilamani M., Apell H.J. and H. Illges. 2002. Purification and characterization of soluble CD21 from human plasma by affinity chromatography and density gradient centrifugation. J Immunol Methods 270:11-18. 
  • Kassahn D., Kolb C., Solomon S., Bochtler P. and H. Illges. 2002. Few human autoimmune sera detect GPI. Nat Immunol 3:411-412.
  • Illges, H. 2002. Die Rolle der Komplementpfade, Fc-Rezeptoren und Antikörper in einem Rheumamodell. Immunologie Aktuell 2:179-181.
  • Rajendran L., Masilamani M., Solomon S., Tikkanen R., Stuermer C.A., Plattner H. and H. Illges. 2003. Asymmetric localization of flotillins/reggies in preassembled platforms confers inherent polarity to hematopoietic cells. Proc Natl Acad Sci U S A 100:8241-8246.
  • Mohanty S., Weiner S.M., Mentele R., Vaith P., Lottspeich F. and H. Illges. 2003. Human IgG1/IgG3 cryoglobulin suggesting lack of allelic exclusion. Mol Immunol 39:1003-1011.
  • Masilamani M., Kassahn D., Mikkat S., Glocker M.O. and H. Illges. 2003. B cell activation leads to shedding of complement receptor type II (CR2/CD21). Eur J Immunol 33:2391-2397.
  • Deininger S.O., Rajendran L., Lottspeich F., Przybylski M., Illges H., Stuermer C.A. and A. Reuter. 2003. Identification of teleost Thy-1 and association with the microdomain/lipid raft reggie proteins in regenerating CNS axons. Mol Cell Neurosci 22:544-554.
  • Wehr C., Eibel H., Masilamani M., Illges H., Schlesier M., Peter H.H. and K. Warnatz. 2004. A new CD21low B cell population in the peripheral blood of patients with SLE. Clin Immunol. 113(2):161-71.
  • Solomon S., Masilamani M., Mohanty S., Schwab J.E., Boneberg E.M., and H. Illges. 2004. Generation of three-dimensional pannus-like tissues in vitro from single cell suspensions of synovial fluid cells from arthritis patients. Rheumatol Int 24:71-76.
  • Masilamani M., von Kempis J. and H. Illges. 2004. Decreased levels of serum soluble complement receptor-II (CR2/CD21) in patients with rheumatoid arthritis. Rheumatology (Oxford) 43:186-190.
  • Masilamani M., Nowack R., Witte T., Schlesier M., Warnatz K., Glocker M.O., Peter H.H. and H. Illges. 2004. Reduction of Soluble Complement Receptor II/CD21 in Systemic Lupus Erythomatosus and Sjoegren´s Syndrome but not Juvenile Arthritis. Scand J Immunol 60(6):625-30.
  • Klett V., Boneberg E.M., Trenz K., Knippers R. and H. Illges. 2004. Hydrostatic pressure induces apoptosis in the human leukemic T cell line Jurkat via the mitochondrial pathway. Scand J Immunol 60(4):403-11.
  • Grottentaler T., von Kempis J., Goldacker S.  and H. Illges. 2006. Soluble CD21 in sera and synovial fluid of arthritic patients. Rheumatol Int., 26 (3): 240-3.
  • Hu, H., Illges H., Gruss C. and R. Knippers. 2005. Distribution of the chromatin-protein DEK on an active and inactive CD21/CR2 gene in two B lymphocyte cell lines. Int Immunol 17(6):789-96.
  • Solomon S., Kassahn D. and H. Illges. 2005. The role of the complement and the FcγR system in the pathogenesis of arthritis. Arthritis Rheum Therapy 7(4):129-35.
  • Möller S., Mix E., Blüggel M., Serrano-Fernández P., Koczan D., Kotsikoris V, Kunz M, Watson M, Pahnke J., Illges H., Kreutzer M., Mikkat S., Thiesen H.J., Glocker M.O., Zettl U.K. and Ibrahim S.M.. 2005. Collection of soluble variants of membrane proteins for transcriptomics and proteomics. In Silico Biology 5, 0028.
  • Spohn, G., Schwarz K. , Maurer P., Illges H., Rajasekaran N., Choi Y. , Jennings G.T. and M.F. Bachmann. 2005. Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles. J Immunol, 175 (9) 6211-8.
  • S. Solomon, Rajasekaran N., Jeisy-Walder E., Snapper S. B.  and H. Illges. 2005. A crucial role for macrophages in the pathology of K/BxN sera induced arthritis. Eur J Immunol, 7 (4) 129-35.
  • Hoefer M.M., Boneberg E.M., Grotegut S., Kusch J. and H. Illges. 2006 Possible tetramerisation of the proteasome maturation factor POMP/proteassemblin/hUmp1 and its subcellular localisation. Int J Biol Macromol. 2006 Mar 16
  • Boneberg E.M., von Seydlitz E., Propster K., Watzl H., Rockstroh B. and H. Illges. 2006. D3 dopamine receptor mRNA is elevated in T cells of schizophrenic patients whereas D4 dopamine receptor mRNA is reduced in CD4(+)-T cells. J Neuroimmunol 173:180-187.
  • Aichem A., Masilamani M., H. Illges .2006. Redox-regulation of CD21-shedding involves signaling via PKC and indicates the formation of a juxtamembrane stalk. J Cell Sci, 119:2892-2902.
  • Sengstake S., Boneberg, E.M. and H. Illges .2006. CD21 and CD62L shedding are both inducible via P2X7Rs. Int Immunol 18:1171-1178.
  • Hoefer, M.M., Boneberg E.M., Grotegut S., Kusch J., and H. Illges. 2006. Possible tetramerisation of the proteasome maturation factor POMP/proteassemblin/hUmp1 and its subcellular localisation. Int J Biol Macromol 38:259-267.
  • Rajendran L., Soazig L.L. and H. Illges, .2007. Raft association and lipid droplet targeting of flotillins are independent of Caveolin-1. Biol Chem 388:307-314.
  • Kneilling M., Hültner L., Pichler B., Mailhammer R., Morawietz L., Solomon S., Eichner M., Sabatino, J., Biedermann T., Krenn V.,Weber V.A., Illges H., Haubner R, and M. Röcken. 2007. Targeted Mast Cell-Silencing silencing protects against joint destruction and angiogenesis in experimental arthritis in mice. Arthritis Rheum 56:1806-1816.
  • Singh A., Blank M., Shoenfeld Y., and H. Illges. 2008. Antiphospholipid syndrome patients display reduced titers of soluble CD21 in their sera irrespective of circulating anti-beta-2-glycoprotein-I autoantibodies. Rheumatol Int. 2008 May;28(7):661-5.
  • Hoefer M.M., Aichem A., Knight, A.M. and H. Illges. 2008. Modulation of murine complement receptor type 2 (CR2/CD21) ectodomain shedding by its cytoplasmic domain. Mol Immunol. 2008 Apr;45(8):2127-37.
  • Masilamani, M., Rajasekaran N., Singh A., Low H., Albus K., Anders S., Behne F., Eiermann P., König K., Mindnich C., Ribarska T.P., and H. Illges. 2008. Systemic reduction of soluble complement receptor II/CD21 during pregnancy to levels reminiscent of autoimmune disease. Rheumatol Int. 2008 Sep;28(11):1137-41.
  • Kienbaum M., Koy C., Montgomery H.V., Drynda H., Lorenz P., Illges H., Tanaka K., Kekow J., Guthke R., Thiesen H.-J., and M.O. Glocker. 2009. Mass Spectrometric Characterization of Apheresis Samples from Rheumatoid Arthritis Patients leads to Knowledge-based Considerations for Improvements of Plasmapheresis Therapy. Proteomics Clin. Appl. 2009, 3, 1-14.
  • Hoefer M. M. and H. Illges. 2009. Ectodomain shedding and generation of two carboxy-terminal fragments of human complement receptor 2/CD21. Mol Immunol 46, 2630-2639.
  • Boneberg E.M., Illges H., Legler D.F., Fürstenberger G. 2009. Soluble CD146 is generated by ectodomain shedding of membrane CD146 in a calcium-induced, matrix metalloprotease-dependent process. Microvascular Research, 2009 Dec;78(3):325-31. Epub 2009 Jul 15.
  • Rajasekaran N., Solomon S., Gajda M., Ohtsu H., Watanabe T., Bräuer R.  and H. Illges. 2009. Histidine decarboxylase but not histamine receptor 1 or 2 deficiency protects from K/BxN serum-induced arthritis. Int Immunol. 2009 Nov; 21(11):1263-8
  • Rajendran L., Beckmann J., Magenau A., Boneberg E.M., Gaus K., Viola A., Giebel B. and H. Illges. 2009. Flotillins are involved in the polarization of primitive and mature hematopoietic cells. PLOS 2009 Dec 22;4(12):e8290.
  • Singh A., Vastert S. J., Prakken B. J. and H. Illges. 2011. Decreased levels of sCD21 and sCD23 in blood of patients with Systemic-Juvenile Arthritis, Polyarticular-Juvenile Arthritis and Pauciarticular-Juvenile Arthritis. Rheumatol Int. 2011 Feb 17. [Epub ahead of print]
  • Frommholz, D., Krämer M., Raffelsieper M. and H. Illges. 2011. Kriminaltechnische Methoden zur Aufklärung von Schussdelikten. Biospektrum in press, DOI;: 10.1007/s12268-011
  • Denninger L., Rasmussen S., Larsen J.M.  , Ørskov C., Poulsen S., Jensen L., Sørensen P., Christensen J.P., Illges H., Ødum N.  and T. Labuda . 2011.
    JNK1 but not JNK2 is required in two mechanistically distinct models of inflammatory arthritis. Am J Pathol. 2011 Oct;179(4):1884-93. Epub 2011 Aug 11
  • Thiel J., Kimmig L., Salzer U., Grudzien M., Lebrecht D., Hagena T., Draeger R., Völxen N., Bergbreiter A., Jennings S., Gutenberger S., Aichem A., Illges H., Hannan J.P., Kienzler A.-K., Rizzi M., Eibel H., Peter H.-H., Warnatz K., Grimbacher B, Rump J.-A., Schlesier M. 2011. Genetic CD21 deficiency is associated with hypogammaglobulinemia. J Allergy Clin Immunol. 2011 Oct 27
  • Frommholz, D., Illges, H. 2012. Maximal locomotor depression follows maximal ankle swelling during the progression of arthritis in K/BxN mice. Rheumatol Int in press, DOI 10.1007/s00296-011-2337-5

Persönlicher Werdegang

  • Studium der Biologie an der Universität Köln (Diplom und Promotion)
  • Postdoctoral fellow (DFG Stipendium) an der University of Alabama, Birmingham, USA
  • Wissenschaftlicher Mitarbeiter an der Universitätsklinik Freiburg
  • Gruppenleiter an der Universität Konstanz
  • Habilitation an der Universität Konstanz für das Fach Immunologie
  • Gründung und Leitung des Biotechnologie Instituts Thrugau, Schweiz
  • Professor für Immunologie und Zellbiologie an der Fachhochschule Bonn-Rhein-Sieg